Will prostate # start or will the Baker brothers just continue to use this stock as a option/cash machine?
A bigger catalysts is coming with the medicare coverage ruling. A go and I suspect they finally let it go.
Rosie got it - there are simply no shares available no matter how hard they try. Good Luck
e.g.:" terryamln Jun 15 • "Total and complete control of this board. I love it!"
....You must be so Proud!
"terryamln" is of course kvncmncdd and fudfighter4 and are clown wanna bes.The GHDX msg bd is also spammed the same way. 40 posts of spam on 2 boards ... they are surely kids.
Multiple studies presented at 2014 ASCO annual meeting reinforce unique, practice-changing value of Oncotype DXÂ® breast cancer test
Demonstrate importance of consistent results from multiple validation studies
Highlight substantial differences between multi-gene tests
Reinforce Genomic Healthâ#$%$™s commitment to improving the quality of treatment decisions for cancer patients
GENEVA, Switzerland--(BUSINESS WIRE)-- Genomic Health, Inc.Â (Nasdaq: GHDX) announced results of three studies with the Oncotype DX breast cancer test at the recent 2014 American Society of Clinical OncologyÂ® (ASCOÂ®) Annual Meeting.
Since GHDX did the stock buyback the only thing the Baker bros want is more shares. (46% of the shares) until they get to 49.9999 % of the company. Felix and co dont care what the price is ( they were buying last year at $36) - they only care the price the company gets sold for. Good Luck
Multiple Studies Presented at ASCO Annual Meeting Demonstrate Unique, Practice-Changing Impact of Oncotype DX to Optimize Cancer Care
GHDX) today announced results of six studies being presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 - June 3 in Chicago, underscoring the practice-changing value of Oncotype DX in pre-invasive and invasive breast cancer and colon cancer.
The presentations include the first Oncotype DX DCIS Scoreâ„¢ clinical decision impact study, which showed a 31 percent change in treatment recommendations. Additionally, a direct comparison study of the Oncotype DX breast cancer test and the ROR score confirmed that the assays are not the same and that the information they provide is not equivalent.
GHDX today announced results of a large, positive study that confirmed that the Oncotype DXÂ® test results for Recurrence ScoreÂ® and quantitative estrogen-receptor (ER) predict late distant recurrence risk in early-stage breast cancer patients after initial tamoxifen therapy, suggesting that Oncotype DX may help identify which patients have greater potential to benefit from extended hormonal treatment beyond five years. Â One of the nine Oncotype DX studies being presented at the 2014 American Society of Clinical Oncology Annual Meeting taking place in Chicago, these data will be presented on June 2 at 8:00 a.m. Central Time.
"As recognized by ASCO's guideline update, recent studies have shown that extending tamoxifen treatment for 10 years is associatedÂ with better outcomes, however, we still need better tools to identify who those patients are," said Norman Wolmark, M.D., chairman of the National Surgical Adjuvant Breast and Bowel Project (NSABP).Â "This study confirms that Oncotype DX can helpÂ better define who is at greatest risk for late recurrences and the potential to benefit from extended tamoxifen, as well as those who are at lower risk and will likely have less absolute benefit from extended tamoxifen and, thus, could be spared prolonged exposure and risk of long-term side effects."
This new study analyzed 668 and 1065 patients from the original NSABP B-14 and B-28 trials, respectively. Median follow-up of 13.9 years (B-14) and 11.2 years (B-28) determined that the Oncotype DX Recurrence Score results were significantly associated with distant recurrence after five years in patients whose tumors had high estrogen receptor expression.Â Specifically, in the NSABP B-14 patients, the association of the continuous Recurrence Score with distant recurrence after five years in the higher
From the folks who brought you "transition!" and canned the Chief Medical officier comes a cleverly hidden in the PR is the notice that **" In the next several months,*** the Company plans to incorporate the trial results into discussions with the regulatory agencies in the United States and Europe to determine next steps for ARIKAYCE in the treatment of NTM lung infections.
Ah ! take a trip down memory lane...1st Qtr! discussions end with regulatory "by second quarter "... and on and on.Insmed did not say 2017 ?? for nothing. YTD +86% on INSM and waiting for the smoke to clear, make no mistake today was smoke and mirrors trading
lol Thanks Cathy " right about 18...can't believe I got it by kvnmcdd •Apr 4, 2014
I was all back in on Monday..(APR 2 @ 19.76)))))).last lot bought and now I am adding. Last week research was a GAME CHANGER. I am excited.kvnmcdd
kvnmcdd • May 13, 2014 3:59 PM
campfund1 • May 13, 2014 4:01 PM
alazoner • May 13, 2014 4:03 PM
OK out 2500 x 0.51= $$$ Lunch money.I know I know these kids dont have a clue but from the looks of my whited out bd and thumbs- their Life is complete! ... the XXXX trade worked better Have more fun kids...
like the "filing!" some investors here are confused.The FDA will rule on if they can file not if the drug is to be approved. That process takes many months and if there is an expedited approval process then late next year is best case for NTM . As we have seen , the company has waited ? how many months just file in Europe after the P3 results in Europe. Then add 13 months till approval for CF - No Us sales looks like the FDA said - you took a chance and didnt do a US trial and the results were not compelling - so live with it - NO US. Good Luck
INSM share price better hold ...else its 10.44 A sell on the news to the offering price of $10 is more probable- ..Good Luck.